$249.56
2.37% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$249.56
-6.51 2.54% 1M
+36.30 17.02% 6M
+77.54 45.08% YTD
+96.99 63.57% 1Y
-5.44 2.13% 3Y
+103.25 70.57% 5Y
+196.51 370.42% 10Y
NYSE, Closing price Mon, Nov 25 2024
+5.78 2.37%
ISIN
US7611521078
Symbol
RMD
Sector

Key metrics

Market capitalization $36.63b
Enterprise Value $37.06b
P/E (TTM) P/E ratio 33.08
EV/FCF (TTM) EV/FCF 27.38
EV/Sales (TTM) EV/Sales 7.71
P/S ratio (TTM) P/S ratio 7.62
P/B ratio (TTM) P/B ratio 7.05
Dividend yield 0.77%
Last dividend (FY24) $1.92
Revenue growth (TTM) Revenue growth 9.88%
Revenue (TTM) Revenue $4.81b
EBIT (operating result TTM) EBIT $1.48b
Free Cash Flow (TTM) Free Cash Flow $1.35b
Cash position $426.36m
EPS (TTM) EPS $7.54
P/E forward 27.71
P/S forward 7.16
EV/Sales forward 7.24
Short interest 6.19%
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a ResMed forecast:

15x Buy
65%
7x Hold
30%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a ResMed forecast:

Buy
65%
Hold
30%
Sell
4%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
4,807 4,807
10% 10%
100%
- Direct Costs 2,080 2,080
4% 4%
43%
2,727 2,727
15% 15%
57%
- Selling and Administrative Expenses 717 717
3% 3%
15%
- Research and Development Expense 311 311
4% 4%
6%
1,699 1,699
24% 24%
35%
- Depreciation and Amortization 216 216
5% 5%
5%
EBIT (Operating Income) EBIT 1,482 1,482
27% 27%
31%
Net Profit 1,113 1,113
23% 23%
23%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Neutral
GlobeNewsWire
21 days ago
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Pal...
Positive
Seeking Alpha
23 days ago
The SPDR S&P 500 ETF Trust posted a loss of 0.89% in October, putting a pause on its strong run in 2024. The Top 15 dividend growth stocks for November 2024 offer an average dividend yield of 1.24% and appear to be about 23% undervalued based on dividend yield theory. Since its inception in September 2020, the watch list has achieved an 11.33% compound annual growth rate.
Positive
Investors Business Daily
about one month ago
S&P 500 giant JPMorgan Chase has been hovering near a buy point since a Q3 earnings beat. Several stocks are in or near buy zones.
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today